Timothy McAlindon to Protein Kinase Inhibitors
This is a "connection" page, showing publications Timothy McAlindon has written about Protein Kinase Inhibitors.
Connection Strength
0.157
-
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 2020 10; 72(10):1694-1706.
Score: 0.157